[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609456":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":46,"locations":56,"responsibleParty":71,"collaborators":11,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":11,"enrollmentInfo":85,"targetDuration":11,"studyType":88,"phases":89,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Mansoura University","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin + Standard of Care","EXPERIMENTAL",null,[13,14],"Drug: Dapagliflozin","Other: Standard Therapy",{"label":16,"type":10,"description":11,"interventionNames":17},"Empagliflozin + Standard of Care",[18,14],"Drug: Empagliflozin",{"label":20,"type":21,"description":22,"interventionNames":23},"Standard of Care Only","ACTIVE_COMPARATOR","Standard treatment protocol(institutional standared) for 6 months without any additional SGLT2 inhibitor.",[14],[25,30,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"DRUG","Dapagliflozin","Dapagliflozin 10 mg PO once daily for 6 months",[9],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"Empagliflozin","Empagliflozin 10 mg PO once daily for 6 month",[16],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"Standard Therapy","immunosuppressive therapy and renoprotective agents for 6 months",[9,16,20],[39,43],{"name":40,"affiliation":41,"role":42},"Moetaza M Soliman, Associate Professor","Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, Mansoura University","STUDY_CHAIR",{"name":44,"affiliation":41,"role":45},"Mustafa O Sharaf El-Deen, Lecturer","STUDY_DIRECTOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":11,"email":51},"Maged S Hariz, PhD Candidate","CONTACT","00201029837454","dr.m.s.binhariz85@gmail.com",{"name":53,"role":49,"phone":54,"phoneExt":11,"email":55},"Ahmed M Abdel-Rahman, Fellow of Nephrology","00201006239797","amans83@mans.edu.eg",[57],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":11},"Urology & Nephrology Center, Mansoura University","RECRUITING","Al Mansurah","Dakahlia Governorate","35516","Egypt","EG",{"type":66,"coordinates":67},"Point",[68,69],31.38069,31.03637,{"lat":69,"lon":68},{"type":72,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Maged Saleh Mohsen Ban Hariz","Pharmacist","100609456","phase-2-sglt2-inhibitors-in-adult-primary-nephrotic-syndrome-100609456",false,"NCT07214818","SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome","Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Adult Patients With Nephrotic Syndrome: A Randomized Controlled Trial","SGLT2-NS","Inclusion Criteria:\n\nAdult patients (≥18 years). Biopsy-confirmed primary nephrotic syndrome (e.g., idiopathic membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis).\n\nEstimated glomerular filtration rate (eGFR) ≥25 mL\u002Fmin\u002F1.73m² using CKD-EPI formula.\n\nOn stable dose of immunosuppressive therapy and renoprotective agents for ≥4 weeks prior to randomization.\n\nAble to signed informed consent.\n\nExclusion Criteria:\n\nDiagnosis of secondary nephrotic syndrome as : diabetes mellitus, lupus nephritis, and amyloidosis.\n\n* Impaired liver functions (ALT or AST values exceeding 3 folds upper limit of normal (ULN) at the screening visit).\n* Glomerular hematuria (red blood cells more than ten cells per high power field (HPF) after routine urinalysis for more than three times in the last 2 weeks).\n* History of severe hypersensitivity or contraindications to dapagliflozin or empagliflozine.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":86,"type":87},75,"ESTIMATED","INTERVENTIONAL",[90,91],"PHASE2","PHASE3","This randomized controlled clinical trial aims to evaluate the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors (dapagliflozin and empagliflozin) in adult patients with primary nephrotic syndrome. The study will compare three groups: dapagliflozin plus standard therapy, empagliflozin plus standard therapy, and standard therapy alone.\n\nThe primary objective is to assess whether SGLT2 inhibitors reduce proteinuria, maintain remission, and prevent relapse. Secondary objectives include evaluating effects on kidney function (eGFR, serum creatinine) and monitoring safety outcomes.\n\nParticipants will continue their baseline standard care and will be followed for 6 months with regular clinical evaluations, laboratory tests, and adverse event monitoring.",[94],"Nephrotic Syndrome",[96,27,31,97,98],"SGLT2 inhibitors","Proteinuria","Primary Nephrotic Syndrome","2026-06-08",{"date":101,"type":102},"2026-06-09","ACTUAL",{"date":104,"type":102},"2025-11-15",{"date":106,"type":87},"2026-09-06",{"name":5,"class":6},1]